Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Growth in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 279,300 shares, a growth of 466.5% from the March 15th total of 49,300 shares. Currently, 37.3% of the shares of the company are sold short. Based on an average trading volume of 2,720,000 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Trading of Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new stake in Windtree Therapeutics, Inc. (NASDAQ:WINT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 29.33% of the company’s stock.

Windtree Therapeutics Trading Up 2.3 %

Shares of WINT stock opened at $1.36 on Tuesday. The firm has a market capitalization of $1.02 million, a P/E ratio of -0.08 and a beta of 0.91. Windtree Therapeutics has a 1 year low of $1.10 and a 1 year high of $737.44. The firm’s fifty day simple moving average is $2.99 and its 200 day simple moving average is $18.39.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.